Naval Daver

Trials

Studies that name Naval Daver as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:32 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT03850574 · Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  Aptose Biosciences Inc. · recruiting · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML · principal investigator
• N/A
  NCT03259230 · Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis

  Swedish Orphan Biovitrum · completed · Hemophagocytic Lymphohistiocytosis · principal investigator
• Ph1/Ph2
  NCT02953561 · Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
• Ph1/Ph2
  NCT02829840 · Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

  M.D. Anderson Cancer Center · withdrawn · Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome · principal investigator
• Ph1/Ph2
  NCT02530476 · Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02420873 · An Open-label Phase II Study of Lorvotuzumab Mertansine

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph2
  NCT02399917 · Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · terminated · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02397720 · Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · completed · Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT02385110 · Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph1
  NCT02225574 · An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

  M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
• Ph1/Ph2
  NCT01893320 · Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
• Ph2
  NCT01787487 · Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  M.D. Anderson Cancer Center · completed · Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · principal investigator
• Ph2
  NCT00038610 · Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

  M.D. Anderson Cancer Center · completed · Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026
  Named on NCT02953561, NCT02399917
• SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
  P50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elizabeth J Shpall · fiscal years 2015 to 2023
  Named on NCT02530476